Galapagos Announces Encouraging New Results From Ongoing Phase 1/2 Study Of CD19 CAR T-Cell Therapy, GLPG5101, In Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
Galapagos Announces Encouraging New Results From Ongoing Phase 1/2 Study Of CD19 CAR T-Cell Therapy, GLPG5101, In Patients With Relapsed/Refractory Non-Hodgkin Lymphoma . (MENAFN - GlobeNewsWire - Nasdaq)     Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity and an encouraging ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108967048/Galapagos-Announces-Encouraging-New-Results-From-Ongoing-Phase-12-Study-Of-CD19-CAR-T-Cell-Therapy-GLPG5101-In-Patients-With-RelapsedRefractory-Non-Hodgkin-Lymphoma
2024-12-07
rss
(MENAFN - GlobeNewsWire - Nasdaq)     Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity and an encouraging ...
Galapagos Announces Encouraging New Results From Ongoing Phase 1/2 Study Of CD19 CAR T-Cell Therapy, GLPG5101, In Patients With Relapsed/Refractory Non-Hodgkin Lymphoma